Interest in low-dose radiotherapy to treat non-malignant conditions, including inflammatory and degenerative disorders of the joints and para-articular soft tissues, has increased substantially in recent years. The clinical efficacy is supported by a large body of evidence, but there is no consensus on the parameters for contouring the PTV. In this recording, Dr. Angel Montero from the Department of Radiation Oncology at the HM Hospitales in Madrid, describes a CT-based contouring atlas for delivering low-dose radiation in the symptomatic treatment of degenerative or inflammatory osteoarticular diseases.
XBeam from Xstrahl Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance for Use in the U.S.
Xstrahl’s XBeam has received FDA 510(k) Clearance for Use in the U.S. The XBeam technology streamlines radiotherapy treatment planning and simplifies patient workflow for treating skin cancer, benign diseases, and palliative care. Explore how this innovation enhances orthovoltage superficial radiotherapy (SRT) and electronic brachytherapy (eBt). With XBeam, you can calculate, protocol and export treatment plans for Xstrahl treatments with Radiant Aura and all other Xstrahl medical devices in the U.S. and worldwide.
